MedTrace Logo

Corifollitropin Alfa and Embryo Morphokinetics

NCT04142190 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1351

Last updated 2019-10-29

No results posted yet for this study

Summary

The study evaluates the influence of corifollitropin alfa (Elonva) on embryo morphokinetics and fertility treatment outcome in comparison to a control group stimulated with Follitropin beta (Puregon).

Conditions

Interventions

DRUG

ELONVA

Elonva is a solution for injection that contains the active substance corifollitropin alfa. It is available as a pre-filled syringe (100 and 150 micrograms).Elonva is used in women who are undergoing fertility treatment to stimulate the development of more than one mature egg at a time in the ovaries.

DRUG

PUREGON

Puregon contains the active substance follitropin beta. fertilisation). Puregon is administered to stimulate the ovaries to produce more than one egg at a time

Sponsors & Collaborators

Principal Investigators

  • Michael Schenk, Dr. · Das Kinderwunsch Institut Schenkg GmbH

Eligibility

Min Age
18 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2018-12-31
Completion
2018-12-31
FDA Drug
Yes

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04142190 on ClinicalTrials.gov